Aaron Pelta is a biopharmaceutical business development executive with more than 20 years of experience across research, clinical and commercial-stage assets. He most recently served as Senior Vice President of Corporate Business Development at Morphic Therapeutic, where he led external partnering, portfolio strategy and commercial planning, including the business development process that culminated in Morphic’s 2024 acquisition by Eli Lilly for $3.2 billion. Prior to joining Morphic, Aaron served as Vice President of Business Development at Arsanis, a clinical stage infectious disease company, where he was a key member of the executive leadership team that completed a private financing, IPO, and reverse merger. Earlier in his career, Aaron held various senior leadership roles at Shire, AMAG and Cubist Pharmaceuticals. He has led the execution of multiple buy and sell side BD transactions, including public-public M&A, covering research to commercial stage assets. His commercial experience spans sales forecasting and analytics through in-line brand management. Aaron received his BS in Chemical Engineering from Tufts University and MBA from the Tuck School of Business at Dartmouth College.